TG Therapeutics, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for TGTX, updated each market day.
TGTX AI Sentiment
AI sees no strong directional signal for TG Therapeutics, Inc. stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About TG Therapeutics, Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.
Sector
Exchange
Market Cap
$5,895,690,411
Cap Tier
Employees
399
Headquarters
NEW YORK, NY
Listed Since
Dec. 14, 1995
Website
TGTX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TGTX Volatility
TG Therapeutics, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
